SSRIs inhib. Minor (1)posaconazole will increase the level or effect of eplerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)azathioprine and hydroxychloroquine sulfate both increase immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Monitor Closely (1)paroxetine and ganaxolone both increase sedation. clonidine, fluoxetine. Administer half of the usual brexpiprazole dose when coadministered with strong CYP2D6 inhibitors. Interaction applies only to oral tetracyclines. fedratinib will increase the level or effect of eplerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)hydroxychloroquine sulfate and rilpivirine both increase QTc interval. bacteriostatic agents may inhibit the effects of bactericidal agents. commonly, these are "non-preferred" brand drugs or specialty To help you remember, take it at the same time each day.If you are taking paroxetine for premenstrual problems, your doctor may direct you to take it every day of the month or just for the 2 weeks before your period through the first full day of your period.Keep taking this medication even if you feel well. If use of moderate CYP3A4 inhibitor unavoidable, reduce mobocertinib dose by ~50% (eg, 160 to 80 mg); closely monitor QTc interval. Avoid or Use Alternate Drug. Serious - Use Alternative (1)hydroxychloroquine sulfate and erythromycin lactobionate both increase QTc interval. You may report side effects to Health Canada at 1-866-234-2345. paroxetine, piroxicam. lofexidine, clonidine. Monitor Closely (1)flibanserin increases levels of clonidine by P-glycoprotein (MDR1) efflux transporter. hydroxychloroquine sulfate and inotuzumab both increase QTc interval. Minor/Significance Unknown. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvY2F0YXByZXMtdHRzLWNsb25pZGluZS0zNDIzODI=, View explanations for tiers and Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. candesartan, eplerenone. Upon initiation or discontinuation of dupilumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. aminolevulinic acid oral, doxycycline. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension. octacosanol increases effects of eplerenone by pharmacodynamic synergism. Monitor Closely (1)eplerenone and potassium citrate/citric acid both increase serum potassium. This website also contains material copyrighted by 3rd parties. serotonin uptake by platelets. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.Serious - Use Alternative (1)clonidine, metoprolol. dabrafenib will decrease the level or effect of eplerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Additive hypotensive effects; potential delirium. Serious - Use Alternative (1)doxycycline increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. hydroxychloroquine sulfate and nilotinib both increase QTc interval. OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Serious - Use Alternative (1)hydroxychloroquine sulfate and mycophenolate both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Use Caution/Monitor. Modify Therapy/Monitor Closely. Contraindicated. Use Caution/Monitor. Minor/Significance Unknown. Increased risk of upper GI bleeding. Avoid or Use Alternate Drug. Serious - Use Alternative (1)paroxetine will increase the level or effect of timolol by affecting hepatic enzyme CYP2D6 metabolism. Coadministration enhances CNS depressant effects. Monitor Closely (1)lamotrigine increases toxicity of paroxetine by unspecified interaction mechanism. Minor/Significance Unknown. Either increases toxicity of the other by pharmacodynamic synergism. This document does not contain all possible drug interactions. Monitor Closely (1)serdexmethylphenidate/dexmethylphenidate increases toxicity of clonidine by unknown mechanism. Minor (1)rufinamide will decrease the level or effect of eplerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)celiprolol, clonidine. restrictions. Contraindicated. Minor/Significance Unknown. Use Caution/Monitor. Either increases toxicity of the other by pharmacodynamic synergism. Minor (1)etravirine will decrease the level or effect of eplerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration with CYP3A4 substrates, particularly those with a narrow therapeutic index, can result in decreased concentrations and loss of efficacy. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. Contraindicated. Most Avoid or Use Alternate Drug. trazodone decreases effects of clonidine by Other (see comment). Monitor Closely (1)doxycycline will increase the level or effect of brexpiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcva2FvcGVjdGF0ZS1wZXB0by1iaXNtb2wtYmlzbXV0aC1zdWJzYWxpY3lsYXRlLTM0MjAzNw==. Modify Therapy/Monitor Closely. bacteriostatic agents may inhibit the effects of bactericidal agents. clonidine, thalidomide. Use Caution/Monitor. Always ask your health care professional for complete information about this product and your specific health needs. Monitor Closely (1)voclosporin, hydroxychloroquine sulfate. clonidine, hydrocodone. Mechanism: pharmacodynamic synergism. Comment: Clonidine may either increase or decrease the blood glucose lowering effect of antidiabetic agents; clonidine may also mask hypoglycemic symptoms. Discontinue buprenorphine if serotonin syndrome is suspected. Minor/Significance Unknown. Minor/Significance Unknown. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Either increases toxicity of the other by serotonin levels. Enhanced CNS depressant effects. Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug. Use Caution/Monitor. Minor/Significance Unknown. Tell your doctor right away if you get sunburned or have skin blisters/redness.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Hydroxychloroquine may cause a condition that affects the heart rhythm (QT prolongation). bismuth subsalicylate decreases levels of minocycline by inhibition of GI absorption. informational and educational purposes only. Serious - Use Alternative (1)doxycycline decreases effects of pivmecillinam by pharmacodynamic antagonism. Monitor Closely (1)clonidine, nabilone. primaquine and hydroxychloroquine sulfate both increase QTc interval. Separate by 2 hours. Diminished symptoms of hypoglycemia. This drug is available at a middle level co-pay. Minor/Significance Unknown. Use Caution/Monitor. Either increases toxicity of the other by sedation. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. HOW TO USE: Read the Medication Guide and, if available, the Patient Information Leaflet provided by your pharmacist before you start taking paroxetine and each time you get a refill. Combining drugs may be therapeutic in patients with Parkinsonism. Avoid or Use Alternate Drug. paroxetine increases effects of metformin by pharmacodynamic synergism. Applies only to oral form of both agents. This drug is available at a higher level co-pay. Avoid or Use Alternate Drug. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Contraindicated. Monitor Closely (1)clonidine, hydroxyzine. doxycycline decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Minor (1)octacosanol increases effects of clonidine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)nitroprusside sodium, clonidine. gilteritinib and paroxetine both increase QTc interval. PRECAUTIONS: Before taking paroxetine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. Avoid or Use Alternate Drug. Minor/Significance Unknown. Avoid or Use Alternate Drug. Either increases effects of the other by pharmacodynamic synergism. Monitor Closely (1)fedratinib will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval. pharmacodynamic antagonism. Monitor Closely (1)isoniazid will increase the level or effect of ropinirole by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Copyright(c) 2022 First Databank, Inc. Use Caution/Monitor. Modify Therapy/Monitor Closely. Initial 50 mg PO qDay; may increase to 50 mg PO q12hr; may take up to four weeks for full therapeutic response; hyperkelemia may occur with doses >100 mg/day, Initial 25 mg PO qDay; may titrate to maximum of 50 mg once daily within 4 weeks as tolerated, Dose adjustments may be required based on potassium levels, Contraindicated if CrCl <50 mL/min or serum creatinine >2 mg/dL in males or >1.8 mg/dL in females, In post-MI CHF patients taking a moderate CYP3A inhibitor, do not exceed 25 mg once daily; in patients with hypertension taking a moderate CYP3A inhibitor, initiate at 25 mg once daily; for inadequate blood pressure response, dosing may be increased to a maximum of 25 mg twice daily, Improving survival of stable patients with LV systolic dysfunction (LVEF 40%) and CHF after an acute myocardial infarction (MI). paroxetine, flurbiprofen. Avoid or Use Alternate Drug. bismuth subsalicylate, esmolol. Avoid or Use Alternate Drug. methylphenidate. Share cases and questions with Physicians on Medscape consult. ropinirole and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Serious - Use Alternative (1)paroxetine will increase the level or effect of methamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen. Use Caution/Monitor. Use Caution/Monitor. Minor/Significance Unknown. Either increases effects of the other by pharmacodynamic synergism. Monitor Closely (1)clonidine, clonazepam. Avoid or Use Alternate Drug. doxycycline will decrease the level or effect of estrogens conjugated synthetic by altering intestinal flora. Monitor Closely (1)clonidine, pramipexole. Use Caution/Monitor. Avoid or Use Alternate Drug. Monitor Closely (1)paroxetine, cariprazine. Modify Therapy/Monitor Closely. Coadministration enhances CNS depressant effects. CNS depressants may increase the toxic effects of selective serotonin reuptake inhibitors; psychomotor impairment may be enhanced. Mechanism: pharmacodynamic synergism. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. clonidine, vildagliptin. Measure the dose carefully using a special measuring device/cup. phenobarbital will decrease the level or effect of ropinirole by affecting hepatic enzyme CYP1A2 metabolism. Monitor Closely (1)hydroxychloroquine sulfate and fostemsavir both increase QTc interval. Avoid or Use Alternate Drug. Use Caution/Monitor. unspecified interaction mechanism. Monitor Closely (1)crofelemer increases levels of eplerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Contraindicated. Severe hypotension or syncope can occur. Monitor CYP3A substrates if coadministered. Modify Therapy/Monitor Closely. Either increases effects of the other by sedation. Additive hypotensive effects; potential delirium. Avoid or Use Alternate Drug. Monitor Closely (1)propranolol, clonidine. Effect of interaction is not clear, use caution. paroxetine will increase the level or effect of oxymorphone by affecting hepatic enzyme CYP2D6 metabolism. A: Generally acceptable. Always ask your health care professional for complete information about this product and your specific health needs. paroxetine will increase the level or effect of loratadine by affecting hepatic enzyme CYP2D6 metabolism. carbamazepine will decrease the level or effect of ropinirole by affecting hepatic enzyme CYP1A2 metabolism. Decreased conversion of tramadol to active metabolite.paroxetine and tramadol both increase serotonin levels. duloxetine Additive hypotensive effects; potential delirium. Use Caution/Monitor. Mechanism: pharmacodynamic synergism. Either increases effects of the other by sedation. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors . Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents. Additive sympatholytic action may worsen sinus node dysfunction and atrioventricular (AV) block. Avoid or Use Alternate Drug. golimumab and hydroxychloroquine sulfate both increase immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Comment: Inhibition of uptake by adrenergic neurons. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents. Minor/Significance Unknown. Use Caution/Monitor. Comment: Clonidine may either increase or decrease the blood glucose lowering effect of antidiabetic agents; clonidine may also mask hypoglycemic symptoms. Avoid or Use Alternate Drug. Use Caution/Monitor. Avoid or Use Alternate Drug. Additive antiplatelet effect may occur; SSRIs and SNRIs may cause platelet serotonin depletion . Minor/Significance Unknown. doxycycline will increase the level or effect of pexidartinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases effects of the other by pharmacodynamic synergism. Mechanism: pharmacodynamic synergism. 2010plaquenil-hydroxychloroquine-sulfate-343205Drugs, 20021073743-overviewDiseases & Conditions, encoded search term (hydroxychloroquine sulfate (Plaquenil)) and hydroxychloroquine sulfate (Plaquenil), Abortion Laws Deny Treatments Needed for Autoimmune Disease, Deucravacitinib and Orelabrutinib Perform Well in Lupus Trials, Proton Pump and VEGF Inhibitors Among Adds to FDA Watch List, Medscape Rheumatologist Compensation Report 2018. Do not substitute tablets with capsules. Use Caution/Monitor. efavirenz will decrease the level or effect of eplerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Immunosuppressants also increase risk of infection with concomitant live vaccines. Monitor for increased risk of QTc interval prolongation. Use Caution/Monitor. paroxetine and meperidine both increase serotonin levels. Minor/Significance Unknown. Use Caution/Monitor. paroxetine will increase the level or effect of nebivolol by affecting hepatic enzyme CYP2D6 metabolism. Diminished symptoms of hypoglycemia. Additive photosensitizing effects. Mechanism: pharmacodynamic synergism. SSRIs inhib. Use Caution/Monitor. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Serious - Use Alternative (1)antithymocyte globulin rabbit and hydroxychloroquine sulfate both increase immunosuppressive effects; risk of infection. doxycycline increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Preventable Adverse Drug Reactions: A Focus on Drug Interactions Modify Therapy/Monitor Closely. Serious - Use Alternative (1)mobocertinib and hydroxychloroquine sulfate both increase QTc interval. doxycycline will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)doxycycline will increase the level or effect of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Serious - Use Alternative (1)paroxetine will increase the level or effect of mexiletine by affecting hepatic enzyme CYP2D6 metabolism. Consider lofexidine dose reduction. This drug is available at a higher level co-pay. Applies only to oral form of both agents. Use Caution/Monitor. If the dose of the concomitant CYP3A4 inhibitor cannot be reduced or discontinued, implant removal may be necessary and the patient should then be treated with a buprenorphine dosage form that permits dose adjustments. Avoid or Use Alternate Drug. Contraindicated. paroxetine, aspirin rectal. Monitor Closely (1)doxycycline decreases effects of cefoxitin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. dupilumab, clonidine. Monitor Closely (1)bismuth subsalicylate, bisoprolol. Either increases toxicity of the other by serotonin levels. Minor/Significance Unknown. Minor/Significance Unknown. Either increases effects of the other by pharmacodynamic synergism. Diminished symptoms of hypoglycemia. Minor/Significance Unknown. Applies only to oral form of both agents. Monitor Closely (1)maprotiline and paroxetine both increase QTc interval. clonidine, oxymorphone. Mechanism: pharmacodynamic synergism. hydroxychloroquine sulfate and amoxapine both increase QTc interval. serotonin uptake by platelets. The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders. Modify Therapy/Monitor Closely. Serious - Use Alternative (1)hydroxychloroquine sulfate and vilanterol/fluticasone furoate inhaled both increase QTc interval. Minor/Significance Unknown. hydroxychloroquine sulfate and saquinavir both increase QTc interval. Increased risk of upper GI bleeding. lorcaserin will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. This document does not contain all possible drug interactions. carbidopa increases effects of eplerenone by pharmacodynamic synergism. Serious - Use Alternative (1)hydroxychloroquine sulfate and dasatinib both increase QTc interval. SSRIs inhib. fosphenytoin decreases levels of doxycycline by increasing metabolism. Either increases toxicity of the other by pharmacodynamic synergism. dichlorphenamide and ropinirole both decrease serum potassium. You may need a different medication. sage decreases effects of lamotrigine by pharmacodynamic antagonism. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling. Use Caution/Monitor.Serious - Use Alternative (1)paroxetine and lorcaserin both increase serotonin levels. Minor/Significance Unknown. However, if your doctor has directed you to take low-dose aspirin for heart attack or stroke prevention (usually 81-162 milligrams a day), you should continue taking it unless your doctor instructs you otherwise. Monitor Closely (1)erythromycin ethylsuccinate and paroxetine both increase QTc interval. Either increases effects of the other by Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Minor/Significance Unknown. Instead, ask your doctor if a different medication would be right for you. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate. If someone has overdosed, remove the patch if possible. Minor/Significance Unknown. Coadministration enhances CNS depressant effects.